Abstract
Ongoing investigation into the relationship between the renin-angiotensin system (RAS) and the progression of diabetic renal disease has persisted for the past two decades. Experimental and clinical evidence suggests that the RAS has a pathogenic role, induced by its haemodynamic and non-haemodynamic mechanisms. The discovery of a local intrarenal RAS provides a rationale for investigating the components of RAS, specifically Angiotensin II (AngII) in the diabetic setting. AngII has multiple effects, including activating intracellular second messengers, transcription factors, extracellular matrix protein and also growth factors and cytokines, which lead to many of the structural and functional changes in the diabetic kidney. The beneficial effects afforded by RAS blockade further implicate AngII in the progression of diabetic nephropathy. Although AngII is a common suspect in the pathogenesis of diabetic nephropathy RAS blockade does not prevent patients from progressing to end stage renal disease. Evaluating other vasoactive factors, which have similar and distinct functions to AngII, will assist in understanding their potential role in the pathogenesis of diabetic nephropathy. A large number of researchers are studying vasoactive factors, however, the case for their role in diabetic nephropathy is inconclusive. Further investigation into the effects of inhibiting vasoactive compounds, including endothelin, urotensin II and vasopeptidases, together with inhibiting RAS, may provide another therapeutic avenue for treating diabetic nephropathy.
Keywords: angiotensin II, diabetic nephropathy, endothelin, urotensin II, vasopeptidase, blockade
Current Pharmaceutical Design
Title: Vasoactive Renal Factors and the Progression of Diabetic Nephropathy
Volume: 10 Issue: 27
Author(s): Lesley Wassef, Robyn G. Langham and Darren J. Kelly
Affiliation:
Keywords: angiotensin II, diabetic nephropathy, endothelin, urotensin II, vasopeptidase, blockade
Abstract: Ongoing investigation into the relationship between the renin-angiotensin system (RAS) and the progression of diabetic renal disease has persisted for the past two decades. Experimental and clinical evidence suggests that the RAS has a pathogenic role, induced by its haemodynamic and non-haemodynamic mechanisms. The discovery of a local intrarenal RAS provides a rationale for investigating the components of RAS, specifically Angiotensin II (AngII) in the diabetic setting. AngII has multiple effects, including activating intracellular second messengers, transcription factors, extracellular matrix protein and also growth factors and cytokines, which lead to many of the structural and functional changes in the diabetic kidney. The beneficial effects afforded by RAS blockade further implicate AngII in the progression of diabetic nephropathy. Although AngII is a common suspect in the pathogenesis of diabetic nephropathy RAS blockade does not prevent patients from progressing to end stage renal disease. Evaluating other vasoactive factors, which have similar and distinct functions to AngII, will assist in understanding their potential role in the pathogenesis of diabetic nephropathy. A large number of researchers are studying vasoactive factors, however, the case for their role in diabetic nephropathy is inconclusive. Further investigation into the effects of inhibiting vasoactive compounds, including endothelin, urotensin II and vasopeptidases, together with inhibiting RAS, may provide another therapeutic avenue for treating diabetic nephropathy.
Export Options
About this article
Cite this article as:
Wassef Lesley, Langham G. Robyn and Kelly J. Darren, Vasoactive Renal Factors and the Progression of Diabetic Nephropathy, Current Pharmaceutical Design 2004; 10 (27) . https://dx.doi.org/10.2174/1381612043383052
DOI https://dx.doi.org/10.2174/1381612043383052 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Sirtuin Modulators: Mechanisms and Potential Clinical Implications
Current Medicinal Chemistry Complications of Anti-Vascular Endothelial Growth Factor Drugs
Current Drug Therapy High Glucose Enhances Neurotoxicity and Inflammatory Cytokine Secretion by Stimulated Human Astrocytes
Current Alzheimer Research Biochemical, Enzymatic and Molecular Properties of Renin/Prorenin Mediated by (Pro)Renin Receptor
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Lessons from the REACH Registry in Europe
Current Vascular Pharmacology <i>Dillenia Indica</i> Fruit Extract Suppressed Diet-induced Obesity in Rats by Down-regulating the mRNA Level of Proadipogenic Transcription Factors and Lipid Metabolizing Enzymes
Current Nutrition & Food Science Acute Renal Failure in Different Malignant Tumors
Current Medicinal Chemistry Voglibose (Basen®, AO-128), One of the Most Important α-Glucosidase Inhibitors
Current Medicinal Chemistry Angiotensin Peptides as AT2 Receptor Agonists
Current Protein & Peptide Science Albumin Competitively Inhibits Glycation of Less Abundant Proteins
Protein & Peptide Letters The Anti-Atherogenic Effects of Thiazolidinediones
Current Diabetes Reviews Islet Amyloid Polypeptide (IAPP): A Second Amyloid in Alzheimer's Disease
Current Alzheimer Research Long Noncoding RNA OIP5-AS1 Overexpression Promotes Viability and Inhibits High Glucose-Induced Oxidative Stress of Cardiomyocytes by Targeting MicroRNA-34a/SIRT1 Axis in Diabetic Cardiomyopathy
Endocrine, Metabolic & Immune Disorders - Drug Targets Phycobilins and Phycobiliproteins Used in Food Industry and Medicine
Mini-Reviews in Medicinal Chemistry Obesity Related Kidney Disease
Current Diabetes Reviews Fanconi-Bickel Syndrome - A Congenital Defect of Facilitative Glucose Transport
Current Molecular Medicine Associations between Periodontitis and Systemic Inflammatory Diseases: Response to Treatment
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Prevention of Contrast Induced Nephropathy
Current Drug Therapy Renin-Angiotensin-Aldosterone System Antagonists and the Prevention of Type 2 Diabetes Mellitus
Current Pharmaceutical Design Proteomic Analysis of Aqueous Humor Proteins Associated with Neovascular Glaucoma Secondary to Proliferative Diabetic Retinopathy
Current Proteomics